Hikma Pharmaceuticals USA Inc. secured FDA approval for Intravenous Acetazolamide Sodium in 1995, expanding its generic portfolio into the IV segment and positioning the company to capture market share in the therapeutic category.
Hikma Pharmaceuticals USA Inc. secured FDA approval for Intravenous Acetazolamide Sodium in 1995, expanding its generic portfolio into the IV segment and positioning the company to capture market share in the therapeutic category.